Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP026 (TQA2226) in Healthy Adult Subjects
NCT06143423Phase 1Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AP026 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Incidence of adverse events up to 2 months, Severity of adverse events up to 2 months and 2 more. Started May 2023; status: terminated.
02
Drugs
AP026
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06143423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143423.